Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Connor26 who wrote (88562)	3/15/2000 1:43:00 PM
From: SFW	Read Replies (1) \| Respond to of 120523

re:the companies say the info has been free and availble all along and things are blown out of proportion - worth reading. That's probably true, but does not change things much. these companies were being valued as though they Owned the genes that they were sequencing, with all the potential profit that comes with such ownership. Now, they are being looked upon as companies that collect data and manipulate it; a very different perception and profit potential IMO. Companies that Do patent specific genes will indeed reap the benefits. Amgen, biogen, immunex, genentech and others are in this category and are being lifted up today vs. the continued weakness in the human genome stocks and second-tier biotechs.